VXGN has other potentially valuable assets, including a «state - of - the - art biopharmaceutical manufacturing facility with a 1,000 - liter bioreactor that can be used to make cell culture or microbial biologic products» and rights to specified percentages of future net sales relating to its anthrax
vaccine product candidate and related technology.
Under the terms of the sale of its assets and rights relating to its anthrax
vaccine product candidate and related technology to Emergent BioSolutions Inc, (Emergent), Emergent may be obligated to pay VXGN up to an additional $ 7M in milestone payments, plus specified percentages of future net sales for 12.5 years beginning from the first commercial sale.
VXGN has other potentially valuable assets, including a «a state - of - the - art biopharmaceutical manufacturing facility with a 1,000 - liter bioreactor that can be used to make cell culture or microbial biologic products» and rights to specified percentages of future net sales relating to its anthrax
vaccine product candidate and related technology.
These events relate primarily to settlement of VaxGen's obligations under its lease of facilities in South San Francisco, and to the potential award of a procurement contract to Emergent BioSolutions (NYSE: EBS) by the U.S. Government for which VaxGen is eligible to receive milestone and royalty payments in connection with Emergent BioSolutions» May 2008 acquisition of VaxGen's recombinant protective antigen (rPA) anthrax
vaccine product candidate and related technology.
Each company has contributed product candidates to the collaboration: Sanofi Pasteur will contribute HSV - 529, a clinical - stage replication - defective HSV
vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent
vaccine product candidate.
Not exact matches
In WP10, iBET will be involved in activities relating to GMP - directed evaluation of
vaccine candidate production processes, production scale - up for
vaccine candidates, definition of specifications for pilot - scale production,
product stability testing and delivery for GLP toxicology studies, as well as the evaluation of development, manufacturing and finishing documentation.
In WP10, iBET will be involved in the GMP - directed evaluation of
vaccine candidate production processes, production scale - up for
vaccine candidates, definition of specifications for pilot - scale production,
product stability testing and delivery for GLP toxicology studies, as well as the evaluation of development, manufacturing and finishing documentation.
As the Global HIV
Vaccine Product Manager for the US Army, Dr. Ake advances the development of HIV vaccine candidates in preclinical and early clinical s
Vaccine Product Manager for the US Army, Dr. Ake advances the development of HIV
vaccine candidates in preclinical and early clinical s
vaccine candidates in preclinical and early clinical studies.
Compilation of an investigational medicinal
product dossier (IMPD) for the clinical trial application for two
candidate vaccines, allowing them to proceed to phase I clinical trials.
iBET will be involved in activities related with GMP - directed evaluation of
vaccine candidate production processes, production scale - up for
vaccine candidates, definition of specifications for pilot - scale production,
product stability testing and delivery for GLP toxicology studies, and evaluation of development, manufacturing and finishing documentation.